

1 **Fixed-Dose Combination Use and Drug Adherence, Healthcare Utilization, and Costs**

2
3 Donglan Zhang, PhD^{1,2,*}, Jun Soo Lee, PhD^{3,*}, Nicole L. Therrien, PharmD, MPH³,
4 Lisa M. Pollack, PhD, MPH, MPT³, Sandra L. Jackson, PhD, MPH³, Xiaobei Dong, PhD⁴,
5 Anand Rajan, MS,¹ Kai Hong, PhD,⁵ Andrew E. Moran, MD, MPH,⁶ and Feijun Luo, PhD³

6
7 * Donglan Zhang and Jun Soo Lee are joint 1st authors with equal contributions.

8
9 **Author Affiliations:**

10 ¹ Center for Population Health and Health Services Research, Department of Foundations of
11 Medicine, New York University Grossman Long Island School of Medicine, Mineola, NY

12 ² Department of Population Health, New York University Grossman School of Medicine, New
13 York, NY

14 ³ Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention,
15 Atlanta, GA

16 ⁴ Joseph J. Zilber College of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI

17 ⁵ Policy Analysis and Engagement Office, Office of Policy, Performance, and Evaluation,
18 Centers for Disease Control and Prevention, Atlanta, GA

19 ⁶ Division of General Medicine, Columbia University Irving Medical Center

20

21 **Correspondence to:**

22 Feijun Luo, PhD

23 Economist

24 Division for Heart Disease and Stroke Prevention

25 Centers for Disease Control and Prevention

26 Phone: 770-488-3896

27 Email: hto1@cdc.gov

28

29 **Word count:** abstract: 341; main text: 3,492

30 Number of tables/figures 5; references: 41

31

32 Conflict of Interest Disclosures: None

33

34 Funding: None

35

36 Disclaimer: The findings and conclusions in this report are those of the authors and do not
37 necessarily represent the official position of the Centers for Disease Control and Prevention. Use
38 of trade names and commercial sources is for identification only and does not imply endorsement
39 by the U.S. Department of Health and Human Services.

40

41 Acknowledgments: The authors are genuinely grateful to Michael Schooley (Centers for Disease
42 Control and Prevention) for their guidance, suggestions, and article review.

43 **Abstract**

44 **BACKGROUND:** Combination-pill therapy using fixed-dose combination (FDC)
45 antihypertensives has the potential to improve hypertension control and management. However,
46 combination-pill therapy remains low. This study aims to assess 1) the association between
47 combination-pill therapy and subsequent medication adherence, healthcare utilization, and costs
48 and 2) the potential to mitigate racial and ethnic disparities in medication adherence, among
49 Medicaid beneficiaries.

50 **METHODS:** A retrospective cohort analysis was conducted using the 2017-2021 Merative™
51 MarketScan® Medicaid claims database. The study sample included adults aged 18-64 years
52 with hypertension, continuously enrolled one year before and after a random index date of
53 prescribed antihypertensives. Combination-pill therapy was compared with multi-pill therapy.
54 The propensity-score overlap weighting method was used to balance characteristics between
55 individuals using combination- and multi-pill therapy. Logistic models were used for medication
56 adherence, linear models for medication possession ratios (MPRs), negative binomial models for
57 healthcare utilization, and generalized linear models for healthcare costs.

58 **RESULTS:** Compared with multi-pill therapy, combination-pill therapy was associated with
59 improved medication adherence (3.17 in MPR, 95% CI: 2.79 - 3.55), fewer hypertension-related
60 emergency department visits (220 per 1,000 individuals, 95% CI: -235 – -204), fewer
61 hospitalizations (153 per 1,000 individuals, 95% CI: -160 – -146), and lower medical costs
62 (\$2,862 per person, 95% CI: -\$3,035 – -\$2,689). However, disparities in medication adherence
63 between non-Hispanic White and non-Hispanic Black adults existed for both FDC and multi-pill
64 therapy.

65 **CONCLUSIONS:** Combination-pill therapy could improve hypertension management and save
66 costs for the Medicaid program and beneficiaries. These findings may inform policies on FDC
67 antihypertensive coverage and programs.

68 **Introduction**

69 Hypertension is a major risk factor for cardiovascular disease, stroke, kidney disease, and
70 dementia,¹⁻³ affecting about half of Americans based on the 2017 American College of
71 Cardiology and American Heart Association (ACC/AHA) definition for hypertension (threshold:
72 130/80 mmHg).⁴ Non-Hispanic Black (NHB) adults have substantially higher hypertension
73 prevalence but lower medication adherence and prevalence of blood pressure control than Non-
74 Hispanic White (NHW) and Hispanic adults.^{5,6}

75 Fixed-dose combination (FDC) therapy that combines ≥ 2 antihypertensive medications into a
76 single pill (a treatment strategy referred to as combination-pill therapy in this study) simplifies
77 medication regimens and has been proven safe and effective.⁷ Combination-pill therapy using
78 FDC antihypertensives may improve medication adherence and hypertension control.⁸ The 2017
79 ACC/AHA guideline recommended lower blood pressure thresholds and using combination-pill
80 antihypertensive therapy as an initial management strategy for some individuals to control
81 hypertension more quickly and effectively.⁹ The 2018 European Society of Cardiology/European
82 Society of Hypertension and the Japanese Society of Hypertension guidelines also highlighted
83 the importance of FDC-antihypertensives for hypertension treatment and recommend initial
84 combination-pill therapy in almost all patients.¹⁰

85 Despite the promise of combination-pill therapy, its utilization for hypertension treatment in
86 the United States remains low.^{11,12} This could be due to several reasons. One is that certain FDC-
87 antihypertensives, although approved, may not be included in health care systems' treatment
88 protocols and insurance coverage formularies.^{13,14} Therapeutic inertia may also play a role, and
89 there are concerns among health care professionals regarding the safety and efficacy, availability
90 of different combinations, insurance coverage, and access to detailed FDC-antihypertensive

91 information.¹⁵ These barriers may particularly affect low-income and racial and ethnic minority
92 populations, who may disproportionately face financial burden if insurance does not cover these
93 drugs.^{16,17} Evidence is lacking regarding whether combination-pill therapy is effective in
94 mitigating racial and ethnic disparities in hypertension management.

95 To address this evidence gap, using large-scale claims data, we conducted an analysis among
96 Medicaid beneficiaries to investigate: 1) the association between combination-pill therapy and
97 subsequent medication adherence, healthcare utilization and medical expenses over a one-year
98 period, and 2) whether the associations between combination-pill therapy and hypertension-
99 related outcomes vary across racial and ethnic groups.

100 **Methods**

101 **Data Sources and Study Population**

102 Data were obtained from the MerativeTM MarketScan[®] multistate Medicaid claims database
103 from 2016 to 2022. To build our study sample (**Appendix Figure 1**), we first identified
104 Medicaid beneficiaries who had ≥ 1 hypertension diagnosis (ICD-10-CM codes I10-I15) and had
105 ≥ 1 pharmacy claims for an antihypertensive medication between January 2017 and December
106 2021 (study period, **Appendix Table 1**). During this period, we selected a random date as the
107 index date to define the time when individuals filled or refilled antihypertensive medications.
108 The random selection of the index date is preferred over identifying an index date based on the
109 order of a pharmacy claim, as the latter would oversample individuals from earlier years
110 compared with later years.¹⁸ A random index date allows for a more even distribution of
111 individuals who initiated medications at different times across the study period and has been
112 widely used in claims data analysis.^{18,19} We then restricted the sample to those who (1) were
113 aged 18-64 years at the index date, (2) were continuously enrolled in one Medicaid insurance
114 plan for the entire 1-year follow-up period post-index date, (3) had one year of data for
115 prescribed antihypertensives before and after the index date.

116 We excluded beneficiaries aged ≥ 65 years who may have been dually eligible for Medicare,
117 as well as those who had a pregnancy diagnosis during the study period, as pregnancy may affect
118 medication regimens.²⁰ In addition, to streamline the comparison between those using
119 combination-pill therapy and those using non-FDC-antihypertensives for two different
120 medication classes (referred to as multi-pill therapy in this study), we excluded beneficiaries who
121 switched between combination-pill therapy and multi-pill therapy. We also excluded those who

122 used only one antihypertensive therapeutic class to create comparable groups for the two therapy
123 types. Finally, when calculating the annual healthcare costs, we identified a subset of adults not
124 covered by capitated health insurance plans because fixed annual payment model plans do not
125 fully reflect healthcare costs incurred when receiving services.²¹

126 **Outcomes**

127 The primary outcomes of the study included 1) antihypertensive medication adherence within
128 one year post-index date, 2) emergency department (ED) visits and inpatient admissions
129 associated with hypertension and cardiovascular disease (CVD) per 1,000 individuals within
130 one-year post-index date, and 3) hypertension-related medical costs (overall, and separately for
131 ED visits and inpatient admissions) within one year post-index date and 4) CVD-related medical
132 costs (overall, and separately for ED visits and inpatient admissions) within one year post-index
133 date. Sensitivity analyses examined all-cause costs. Hypertension-related and CVD-related
134 healthcare utilization and total medical costs were defined based on the presence of the
135 respective diagnosis codes (hypertension: ICD-10-CM codes I10-I15; CVD: ICD-10-CM codes
136 I00-I78).²²

137 Medication adherence was measured using the medication possession ratio (MPR), with MPR
138 $\geq 80\%$ indicating adequate adherence to antihypertensive medications.^{23,24} The average MPR was
139 computed as the ratio of the total days of antihypertensive drug supply to the number of days in
140 each year.²³ For combination-pill therapy, we derived the average MPRs for all available FDC-
141 antihypertensives in the database (**Appendix Table 2**) and for the seven antihypertensive
142 therapeutic classes including Angiotensin-Converting Enzyme (ACE) inhibitors, angiotensin
143 receptor blockers (ARB), beta-blockers, calcium channel blockers (CCB), diuretics, other
144 antihypertensives, and renin-angiotensin system antagonists separately, along with the

145 corresponding generic drug names.²⁴ For multi-pill therapy, we derived the average MPRs for
146 each antihypertensive medication.

147 For our secondary outcomes, we assessed 1) Medicaid insurance payments (including all
148 adjusted payments for healthcare services from the Medicaid program), 2) patient out-of-pocket
149 (OOP) costs (including copay, coinsurance and deductibles) and 3) total costs (the sum of the
150 Medicaid insurance payments and patient OOP costs for combination-and multi-pill therapy per
151 individual. All secondary outcomes reflect results within one-year post-index date.

152 All outcomes were stratified by race and ethnicity (NHW, NHB, and Hispanic populations).
153 We did not stratify by other racial groups due to their high heterogeneity.

154 **Exposure**

155 Combination-pill therapy was defined as having a pharmacy claim for ≥ 1 FDC-
156 antihypertensive medication and no other antihypertensive medications from the index date
157 through the follow-up period. The comparison was multi-pill therapy, defined as having no
158 claims for FDC-antihypertensives but having claims for ≥ 2 different antihypertensive medication
159 classes from the index date through the follow-up period.

160 **Statistical Analysis**

161 We used propensity score (PS) overlap weighting methods to balance characteristics between
162 individuals using combination- and multi-pill therapy (**Appendix Figure 2**).^{25,26} In calculating
163 the PS, we included age groups (18-34, 35-44, 45-54, and 55-64 years), gender, race and
164 ethnicity (NHW, NHB, Hispanic, and other racial groups), dummy indicators for risk factors
165 (alcohol use, tobacco use, obesity, and lipid disorders), and 12 comorbidities identified in the
166 Charlson comorbidity index (CCI, excluding myocardial infarction, congestive heart failure,

167 peripheral vascular disease, cerebrovascular disease, and renal disease from the original CCI
168 because these comorbidities may be in the causal pathways between antihypertensive medication
169 use and CVD outcomes).²⁷. All sociodemographic and comorbidity variables were measured in
170 the one-year period prior to the index date.

171 We employed logistic models for medication adherence and linear models for MPRs. We then
172 employed negative binomial models to estimate all healthcare utilization outcomes. We utilized
173 generalized linear models with gamma distribution and log link function to accommodate the
174 skewed distribution of healthcare costs.²⁸ In sensitivity analyses, we included those who used
175 both combination-pill *and* multi-pill therapy in the same year (to create a more inclusive
176 definition of the combination-pill therapy group, allowing for inclusion in the exposure group of
177 patients who may have switched between regimens or who may have been taking an FDC-
178 antihypertensive along with additional antihypertensive agents simultaneously) and tested the
179 robustness of the results.

180 All models were additionally adjusted for fixed effects for the year and month of the index
181 date to control for time-invariant fixed effects within a year or a month. In each model, we
182 compared outcomes between combination- and multi-pill therapy groups within the entire
183 population, as well as within each race and ethnicity. We tested whether outcomes between
184 combination- and multi-pill therapy groups differed by race/ethnicity by examining the statistical
185 significance of interaction terms between therapy type and race/ethnicity.

186 Average marginal effects and corresponding 95% confidence intervals (95% CI) were
187 reported. Sensitivity analyses were conducted to assess the association between combination-pill
188 therapy and all-cause healthcare utilization, as combination-pill therapy may have spillover
189 effects on other disease outcomes and related healthcare utilization. All analyses were conducted

190 using Stata SE 17.0 statistical software (StataCorp, College Station, TX) and SAS version 9.4
191 (SAS 9.4, Cary, NC. SAS Institute Inc.).

192 **Results**

193 After sample selection, a total of 325,600 adults with Medicaid coverage were included in the
194 analysis of healthcare utilization outcomes. In the subset analysis among those not covered by
195 capitated insurance, 128,528 adults were included in the assessment of cost outcomes (**Appendix**
196 **Figure 1**).

197 **Sample Characteristics**

198 Among 325,600 adults, 29,328 (9%) used combination-pill therapy to manage their
199 hypertension, while 296,272 (91%) used multi-pill therapy (**Table 1**). Compared with the multi-
200 pill therapy group, the combination-pill therapy group was significantly younger (48.2 vs. 49.4,
201 $p < 0.001$) and had a higher proportion of females (64.11% vs. 55.01%, $p < 0.001$) and NHB adults
202 (33.12% vs. 28.15%, $p < 0.001$). The combination-pill therapy group also had a lower proportion
203 of alcohol and tobacco use (both $p < 0.001$) and a lower proportion of some comorbidities
204 (dementia, chronic pulmonary disease, rheumatic disease and diabetes), but higher proportion of
205 others (obesity, diabetes, and lipid disorders) (all $p < 0.001$). After weighting the sample using the
206 PS overlap approach, the characteristics between individuals using combination-pill and multi-
207 pill therapy were not statistically significant (**Appendix Figure 2**).

208 **Association between Combination-Pill Therapy and Medication Adherence**

209 After PS overlap weighting, compared with multi-pill therapy, combination-pill therapy was
210 associated with, on average, an 8.5 percentage point (95% CI: 7.9 – 9.1) higher likelihood of
211 medication adherence ($\text{MPR} \geq 80\%$) or 3.17 (95% CI: 2.79 – 3.55) higher average MPR (**Table**
212 **2**). The associations were strongest among NHW adults, who had a 9.7 percentage point (95%
213 CI: 8.9 – 10.5) higher likelihood of medication adherence when using combination-pill vs multi-

214 pill therapy, compared with the 6.9 percentage point (95% CI: 5.9 – 7.9) higher likelihood
215 among NHB and 5.7 percentage point (95% CI: 2.9 – 8.5) among Hispanic adults (p<0.001).

216 **Association between Combination-Pill Therapy and Healthcare Utilization and Costs**

217 Compared with multi-pill therapy, those using combination-pill therapy experienced, on
218 average, 220 fewer hypertension-related ED visits (95% CI: -235 – -204), 153 fewer
219 hypertension-related inpatient admissions (95% CI: -160 – -146), 270 fewer CVD-related ED
220 visits (95% CI: -287 – -254), and 181 fewer CVD-related inpatient admissions (95% CI: -189 – -
221 173) per 1,000 individuals one year after the index date (**Table 3**). These effects were most
222 pronounced among NHB adults. Compared with multi-pill therapy, combination-pill therapy use
223 among NHB adults was associated with reductions of 287 (95% CI: -318 – -256) hypertension-
224 related ED visits, 192 (95% CI: -204 – -180) hypertension-related inpatient visits, 337 (95% CI: -
225 368 – -305) CVD-related ED visits, and 215 (95% CI: -228 – -202) CVD-related inpatient visits
226 per 1,000 individuals one year after the index date. Among NHW adults, combination-pill
227 therapy was associated with reductions of 172 (95% CI: -192 – -152) hypertension-related ED
228 visits, 134 (95% CI: -142 – -125) hypertension-related inpatient visits, 225 (95% CI: -246 – -
229 204) CVD-related ED visits, and 167 (95% CI: -177 – -158) CVD-related inpatient visits per
230 1,000 individuals one year after the index date. Combination-pill therapy was associated with the
231 least reduction in ED and inpatient visits among Hispanic adults.

232 Among those with non-capitated Medicaid plans, compared with multi-pill therapy,
233 combination-pill therapy was associated with a \$2,862 per-person reduction in total
234 hypertension-related medical costs one year after the index date (95% CI: -\$3,035 – -\$2,689),
235 including \$225 (95% CI: -\$251 – -\$199) for hypertension-related ED visits and \$2,280 (95% CI:
236 -\$2,464 – -\$2,096) for hypertension-related inpatient admissions (**Table 4**). Combination-pill

237 therapy was also associated with a reduction of total CVD-related medical costs by \$3,779 per
238 person (95% CI: -\$3,978 – -\$3,581), with reductions of \$269 (95% CI: -\$295 – -\$242) for CVD-
239 related ED visits and \$2,798 (95% CI: -\$3,018 – -\$2,578) for CVD-related inpatient visits.
240 Among NHB adults, combination-pill therapy was associated with a reduction of hypertension-
241 related medical costs by \$3,896 per-person (95% CI: -\$4,198 – -\$3,595), compared with \$2,126
242 (95% CI: -\$2,339 – -\$1,912) for NHW adults and \$1,259 (95% CI: -\$1,584 – -\$934) for Hispanic
243 adults ($P < 0.001$). In addition, combination-pill therapy was associated with a reduction of CVD-
244 related medical costs by \$4,914 per-person (95% CI: -\$5,258 – -\$4,571) among NHB adults,
245 compared with \$3,012 (95% CI: -\$3,255 – -\$2,769) for NHW adults and \$1,727 (95% CI: -
246 \$2,095 – -\$1,359) for Hispanic adults ($p < 0.001$).

247 **Sensitivity Analyses**

248 In sensitivity analyses, compared with multi-pill therapy, combination-pill therapy was
249 associated with a significant reduction in all-cause healthcare utilization and medical costs one
250 year after the index date, with a stronger association observed among NHB adults ($p < 0.001$,
251 **Appendix Table 3 and 4**). Further, 82,126 (22%) used both combination- and multi-pill therapy
252 during the same year, (**Appendix Table 5**). Including individuals who used both therapies did
253 not alter the findings or conclusions (**Appendix Figure 3, Appendix Table 6-9**).

254 **Comparison of Annual and Out-Of-Pocket Costs between Combination-and Multi-Pill 255 Therapy groups**

256 The annual per-person costs for combination-pill therapy (\$111 95% CI: \$107 – \$115) were
257 significantly lower than those for multi-pill therapy (\$273, 95% CI: \$270 – \$275). The patient
258 OOP costs for combination-pill therapy (\$8) were also lower than those for multi-pill therapy

259 (\$13) ($P < 0.001$) (**Figure 1**). However, among those who used combination-pill therapy, NHB
260 beneficiaries had similar annual medication costs (\$110) to NHW (\$107) but significantly higher
261 than Hispanic adults (\$61).

262 **Discussion**

263 In this cohort study of Medicaid beneficiaries with hypertension, we found that 9% used
264 combination-pill therapy to manage their blood pressure. Combination-pill therapy was
265 significantly associated with higher medication adherence, fewer ED visits and hospitalizations,
266 and lower medical costs compared with multi-pill therapy. Combination-pill therapy was also
267 associated with lower Medicaid payments and patient OOP costs than multi-pill therapy.
268 However, improvement in medication adherence was smaller among NHB adults than NHW
269 adults for combination-pill therapy versus multi-pill therapy, but NHB adults showed a more
270 pronounced association with reduced healthcare utilization and costs.

271 Compared with the reported prevalence of FDC-antihypertensive/combination-pill therapy
272 among all U.S. adults with hypertension based on National Health and Nutrition Examination
273 Survey (NHANES) 2017-March 2020 (27.8%),⁹ we found a lower prevalence of Medicaid
274 beneficiaries using FDC-antihypertensives exclusively (9%, our main analysis definition of
275 combination-pill therapy) or using a mix of FDC-antihypertensives and other antihypertensives
276 during the same year (22%; our more inclusive sensitivity analysis definition of combination-pill
277 therapy) between 2017-2021. Previous reports indicated a decrease in FDC-antihypertensive use
278 from 2012 to 2020,⁹ with Medicare and Medicaid FDC claims decreasing from 2016 to 2020.²⁹
279 The majority of FDC-antihypertensives are available in generic form,²⁹ and our analysis showed
280 that Medicaid payments and patient OOP costs were lower for combination-pill therapy. Given
281 the small proportion of Medicaid beneficiaries with hypertension using combination-pill therapy,
282 barriers to use of combination-pill therapy may not be attributed to costs. Prior work has
283 documented barriers including lack of sufficiently diverse FDC-antihypertensive therapeutic
284 options with respect to medication classes and dosage; one study estimated that nearly two-thirds

285 of US adults with hypertension were using a regimen not available as an FDC-antihypertensive
286 product.¹¹

287 Consistent with the literature,^{30,31} our analysis demonstrated that combination-pill therapy was
288 associated with significantly higher medication adherence. However, combination-pill therapy
289 was less associated with medication adherence in NHB adults (1.76, 95% CI: 1.09 - 2.44)
290 compared with NHW adults (3.88, 95% CI: 3.34 - 4.42). This finding may be attributable to
291 several reasons. First, the majority of FDC-antihypertensives were combinations of ACE
292 inhibitors or ARBs plus thiazide diuretics,²⁹ and ACE inhibitors and ARBs may be insufficient
293 for improving hypertension control for NHB adults, possibly due to poorer medication adherence
294 and/or differences in physiological pathways.³²⁻³⁴ The AHA/ACC guideline recommends initial
295 antihypertensive treatment with a thiazide diuretic or CCBs for NHB adults. However, there are
296 no CCB/thiazide diuretic FDC-antihypertensives, which represents a gap for guideline-
297 recommended combination-pill therapy for NHB adults, who may have a less robust response to
298 ACEIs, ARBs, and beta-blockers.³⁵ Second, there may be differences in plan enrollment and
299 coverage formularies at the state or plan level, particularly in states with managed care
300 organizations. As shown in our analysis, there were some slight variations in costs for NHB
301 beneficiaries compared with NHW and Hispanic beneficiaries. NHB beneficiaries may be more
302 likely to be enrolled in plans with higher cost-sharing responsibilities compared with NHW and
303 Hispanic Medicaid beneficiaries.³⁶ However, our data did not include data on insurance benefit
304 designs, so this is beyond the scope of the present analysis and may be investigated in national
305 Medicaid claims databases in the future.

306 We observed that combination-pill therapy was associated with greater reductions in ED and
307 inpatient visits among NHB adults compared with NHW adults, despite a smaller association

308 with medication adherence. This could be because NHB adults initially had much lower
309 medication adherence and higher healthcare utilization and costs. Thus, they might benefit more
310 from using combination-pill therapy. If NHB adults had medication adherence comparable to
311 NHW adults, the reduction in healthcare utilization and costs might have been even larger. In
312 contrast, Hispanic adults had higher medication adherence than NHB adults initially, but the
313 lowest healthcare utilization and costs. Previous studies have reported that Hispanic adults are
314 less likely to seek health care due to language, cultural barriers, and immigration status.³⁷ This
315 could partially explain why the associations between combination-pill therapy and lower
316 healthcare utilization and costs were smaller among Hispanic adults compared with NHW adults.

317 Our study has important implications. While combination-pill therapy has the potential to
318 improve medication adherence, the available options in the US may not offer the variety of class
319 and dose combinations preferred by clinicians. An analysis of 2015-2020 NHANES data found
320 189 unique therapeutic class combination regimens among US adults using antihypertensives,
321 only 7 of which (3.7%) were available as FDC-antihypertensives.¹¹ Similar findings are seen
322 among combination regimens in the Systolic Blood Pressure Intervention Trial (SPRINT).^{11,38}
323 There are no available combinations containing four antihypertensives, which were used by over
324 25% of SPRINT participants. The availability of only two- or three-drug FDC-antihypertensives,
325 and no four- or five-drug FDC-antihypertensives, limits the treatment options for patients in the
326 U.S. who require multiple antihypertensives to achieve hypertension control.³⁹ Furthermore, the
327 need for triple and quadruple drug combinations may increase because ACC/AHA hypertension
328 treatment guidelines have recommended more intensive treatment goals (lower target blood
329 pressures).⁴⁰ Factors such as drug shortages, changes in insurance coverage or cost-sharing tiers,
330 or concerns about side effects may deter initiation or prompt switching from FDC-

331 antihypertensives to other antihypertensives. Moreover, while 90% of Medicaid plans cover at
332 least four FDC-antihypertensives, and 100% cover at least one FDC-antihypertensive, individual
333 drug coverage and costs vary by state Medicaid programs.³⁹ Some drugs are on preferred (Tier 1)
334 or non-preferred (Tier 2) tiers, which may influence clinicians' prescribing behavior. To address
335 these gaps, policymakers and pharmaceutical companies could consider exploring and
336 broadening FDC-antihypertensive options with a wider range of drug class combinations to suit
337 the variety of treatment needs faced by prescribing clinicians.⁴¹

338 **Limitations**

339 We acknowledge several limitations. First, we only tracked short-term outcomes over a single
340 year of combination-pill therapy use, leaving the long-term impacts of combination-pill therapy,
341 such as mortality and productivity, unknown. Second, as we used a multistate Medicaid claims
342 database, our findings may not be generalizable to individuals covered by other types of
343 insurance, particularly because the price of FDC-antihypertensives covered by Medicaid tends to
344 be lower than that of equivalent drugs covered by Medicare and private insurance.²⁹
345 Additionally, individual drug coverage and costs vary by state Medicaid programs, which may
346 lead to disparities in access and treatment patterns across different states. However, our data do
347 not include state identifiers, preventing us from differentiating Medicaid medication coverage
348 policies or decisions at the state level. Third, our claims database only shows whether
349 prescriptions were filled and picked up, not if patients actually took the medications. In addition,
350 we could not analyze data at the prescribing clinician level, accounting for variance due to
351 clinician behavior. These issues may lead to potentially overestimation of medication adherence.
352 Fourth, our main analysis focused on individuals exclusively using combination-pill therapy
353 (excluding those who used both combination-pill therapy and other antihypertensives in a single

354 year), which may limit generalizability. However, our sensitivity analyses included individuals
355 who used both combination- and multi-pill therapy in the same year, and results were consistent
356 with the main findings. Finally, we could not ascertain the doses of FDC-antihypertensives,
357 which may affect the healthcare utilization outcomes we assessed.

358 **Conclusions**

359 This large-scale study among Medicaid beneficiaries in multiple states (5 to 8 states from year
360 to year) across the US found that combination-pill therapy was associated with higher
361 medication adherence, lower healthcare utilization, and lower healthcare costs for the Medicaid
362 program and beneficiaries. However, the magnitude of these associations differs by racial and
363 ethnic groups. These research findings may help inform policies related to FDC-antihypertensive
364 medication coverage or formulary decisions, as well as programs aimed at improving medication
365 adherence and hypertension control. In addition, our findings can provide important evidence for
366 clinicians when selecting antihypertensive medications for patients.

367 **References**

- 368 1. Kokubo Y, Iwashima Y. Higher blood pressure as a risk factor for diseases other than
369 stroke and ischemic heart disease. *Hypertension*. 2015;66(2):254-259.
- 370 2. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. *Hypertension*.
371 2020;75(2):285-292.
- 372 3. Burnier M, Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney
373 disease. *Circulation research*. 2023;132(8):1050-1063.
- 374 4. Carey RM, Whelton PK, Committee* AAHW. Prevention, detection, evaluation, and
375 management of high blood pressure in adults: synopsis of the 2017 American College of
376 Cardiology/American Heart Association Hypertension Guideline. *Annals of internal medicine*.
377 2018;168(5):351-358.
- 378 5. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults
379 aged 18 and over: United States, 2017–2018. 2020;
- 380 6. Aggarwal R, Chiu N, Wadhwa RK, et al. Racial/ethnic disparities in hypertension
381 prevalence, awareness, treatment, and control in the United States, 2013 to 2018.
382 *Hypertension*. 2021;78(6):1719-1726.
- 383 7. Salam A, Huffman MD, Kanukula R, et al. Two - drug fixed - dose combinations of blood
384 pressure - lowering drugs as WHO essential medicines: an overview of efficacy, safety, and
385 cost. *The Journal of Clinical Hypertension*. 2020;22(10):1769-1779.
- 386 8. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on
387 adherence to prescription medications. *Journal of general internal medicine*. 2008;23:611-614.
- 388 9. Mobley CM, Bryan AS, Moran AE, Derington CG, Zhang Y, Bellows BK. Fixed - dose
389 combination medication use among US adults with hypertension: a missed opportunity. *Journal*
390 *of the American Heart Association*. 2023;12(4):e027486.
- 391 10. Mahfoud F, Kieble M, Enners S, et al. Use of fixed-dose combination antihypertensives
392 in Germany between 2016 and 2020: an example of guideline inertia. *Clinical Research in*
393 *Cardiology*. 2023;112(2):197-202.
- 394 11. Derington CG, Bress AP, Herrick JS, et al. Antihypertensive medication regimens used
395 by US adults with hypertension and the potential for fixed - dose combination products: the
396 national health and nutrition examination surveys 2015 to 2020. *Journal of the American Heart*
397 *Association*. 2023;12(11):e028573.
- 398 12. Derington CG, King JB, Herrick JS, et al. Trends in antihypertensive medication
399 monotherapy and combination use among US adults, National Health and Nutrition Examination
400 Survey 2005–2016. *Hypertension*. 2020;75(4):973-981.
- 401 13. DiPette DJ, Skeete J, Ridley E, et al. Fixed - dose combination pharmacologic therapy
402 to improve hypertension control worldwide: clinical perspective and policy implications. *The*
403 *Journal of Clinical Hypertension*. 2019;21(1):4.
- 404 14. Esba LCA, Yousef C, Ismail S, et al. Fixed dose combinations: a formulary decision
405 guide. *Health Policy and Technology*. 2021;10(2):100500.
- 406 15. DiPette DJ, Goughnour K, Zuniga E, et al. Standardized treatment to improve
407 hypertension control in primary health care: The HEARTS in the Americas Initiative. *The Journal*
408 *of Clinical Hypertension*. 2020;22(12):2285-2295.
- 409 16. Kogut SJ. Racial disparities in medication use: imperatives for managed care pharmacy.
410 *Journal of managed care & specialty pharmacy*. 2020;26(11):1468-1474.
- 411 17. Fiscella K, Sanders MR. Racial and ethnic disparities in the quality of health care.
412 *Annual review of public health*. 2016;37:375-394.
- 413 18. Bødkegaard K, Selmer RM, Hallas J, et al. Using the waiting time distribution with
414 random index dates to estimate prescription durations in the presence of seasonal stockpiling.
415 *Pharmacoepidemiology and Drug Safety*. 2020;29(9):1072-1078.

- 416 19. Klungel OH, Heckbert SR, Longstreth Jr W, et al. Antihypertensive drug therapies and
417 the risk of ischemic stroke. *Archives of internal medicine*. 2001;161(1):37-43.
- 418 20. Chandrasekaran S, Badell ML, Jamieson DJ. Management of chronic hypertension
419 during pregnancy. *JAMA*. 2022;327(17):1700-1701.
- 420 21. Holahan J, Suzuki S. Medicaid managed care payment methods and capitation rates in
421 2001. *Health Affairs*. 2003;22(1):204-218.
- 422 22. Lee JS, Bhatt A, Pollack LM, et al. Racial and Ethnic Differences in Hypertension-
423 Related Telehealth and In-Person Outpatient Visits Before and During the COVID-19 Pandemic
424 Among Medicaid Beneficiaries. *Telemedicine and e-Health*. 2024;
- 425 23. Canfield SL, Zuckerman A, Anguiano RH, et al. Navigating the wild west of medication
426 adherence reporting in specialty pharmacy. *Journal of managed care & specialty pharmacy*.
427 2019;25(10):1073-1077.
- 428 24. Lee JS, Segura Escano R, Therrien NL, et al. Antihypertensive Medication Adherence
429 and Medical Costs, Health Care Utilization, and Labor Productivity among Persons with
430 Hypertension. *medRxiv*. 2024:2024.04. 15.24305866.
- 431 25. Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that
432 mimics attributes of a randomized clinical trial. *Jama*. 2020;323(23):2417-2418.
- 433 26. Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights.
434 *American journal of epidemiology*. 2019;188(1):250-257.
- 435 27. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10
436 version of the Charlson comorbidity index predicted in-hospital mortality. *Journal of clinical
437 epidemiology*. 2004;57(12):1288-1294.
- 438 28. Deb P, Trivedi PK. The structure of demand for health care: latent class versus two-part
439 models. *Journal of health economics*. 2002;21(4):601-625.
- 440 29. Essa M, Ross JS, Dhruva SS, Desai NR, Spatz ES, Faridi KF. Utilization of Fixed-Dose
441 Combination Treatment for Hypertension in Medicare and Medicaid From 2016 to 2020.
442 *Circulation: Cardiovascular Quality and Outcomes*. 2024;17(5):e010697.
- 443 30. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations
444 improve medication compliance: a meta-analysis. *The American journal of medicine*.
445 2007;120(8):713-719.
- 446 31. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination
447 antihypertensive medications, adherence, and clinical outcomes: a population-based
448 retrospective cohort study. *PLoS medicine*. 2018;15(6):e1002584.
- 449 32. Ogedegbe G, Shah NR, Phillips C, et al. Comparative effectiveness of angiotensin-
450 converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive
451 blacks versus whites. *Journal of the American College of Cardiology*. 2015;66(11):1224-1233.
- 452 33. Flack JM, Buhnerkempe MG. Race and antihypertensive drug therapy: edging closer to
453 a new paradigm. *Am Heart Assoc*; 2022. p. 349-351.
- 454 34. Gu A, Yue Y, Desai RP, Argulian E. Racial and ethnic differences in antihypertensive
455 medication use and blood pressure control among US adults with hypertension: the National
456 Health and Nutrition Examination Survey, 2003 to 2012. *Circulation: Cardiovascular Quality and
457 Outcomes*. 2017;10(1):e003166.
- 458 35. Derington CG, Cohen JB, Bress AP. Restoring the upward trend in blood pressure
459 control rates in the United States: a focus on fixed-dose combinations. *Journal of human
460 hypertension*. 2020;34(9):617-623.
- 461 36. Donohue JM, Cole ES, James CV, Jarlenski M, Michener JD, Roberts ET. The US
462 Medicaid program: coverage, financing, reforms, and implications for health equity. *Jama*.
463 2022;328(11):1085-1099.
- 464 37. Escobedo LE, Cervantes L, Havranek E. Barriers in healthcare for Latinx patients with
465 limited English proficiency—a narrative review. *Journal of general internal medicine*.
466 2023;38(5):1264-1271.

- 467 38. King JB, Derington CG, Herrick JS, et al. Single-Pill Combination Product Availability of
468 the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the
469 Systolic Blood Pressure Intervention Trial. *Hypertension*. 2023;80(8):1749-1758.
- 470 39. *Centers for Disease Control and Prevention. Fixed-Dose Combination Antihypertensive*
471 *Medications Coverage by State Medicaid and Medicaid Managed Care Organizations. Atlanta,*
472 *GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human*
473 *Services; 2022. . Accessed May 22, 2024.*
- 474 40. Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017
475 ACC/AHA high blood pressure guideline. *Circulation*. 2018;137(2):109-118.
- 476 41. US Food & Drug. Hypertension: Developing Fixed-Dose Combination Drugs for
477 Treatment. Accessed May 31, 2024. [https://www.fda.gov/regulatory-information/search-fda-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-developing-fixed-dose-combination-drugs-treatment)
478 [guidance-documents/hypertension-developing-fixed-dose-combination-drugs-treatment](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-developing-fixed-dose-combination-drugs-treatment)

479

Table 1. Summary Statistics of Sample Characteristics

	All	Combination-pill therapy	Multi-pill therapy	P-values
	N=325,600 (100%)	N=29,328 (9%)	N=296,272 (91%)	
Age, mean (SD)	49.3 (10.1)	48.2 (9.9)	49.4 (10.2)	<0.001
Age groups, n (%)				
18-34	31,428 (9.65%)	2,884 (9.83%)	28,544 (9.63%)	0.27
35-44	67,531 (20.74%)	7,415 (25.28%)	60,116 (20.29%)	<0.001
45-54	102,795 (31.57%)	9,537 (32.52%)	93,258 (31.48%)	<0.001
55-64	123,846 (38.04%)	9,492 (32.36%)	114,354 (38.60%)	<0.001
Female, n (%)	181,776 (55.83%)	18,802 (64.11%)	162,974 (55.01%)	<0.001
Race categories, n (%)				
Non-Hispanic White	174,306 (53.53%)	14,527 (49.53%)	159,779 (53.93%)	<0.001
Non-Hispanic Black	93,122 (28.60%)	9,712 (33.12%)	83,410 (28.15%)	<0.001
Hispanic	13,736 (4.22%)	1,290 (4.40%)	12,446 (4.20%)	0.11
Other race groups	44,436 (13.65%)	3,799 (12.95%)	40,637 (13.72%)	<0.001
Risk factors, n (%)				
Alcohol use	21,338 (6.55%)	867 (2.96%)	20,471 (6.91%)	<0.001
Tobacco use	83,496 (25.64%)	5,160 (17.59%)	78,336 (26.44%)	<0.001
Obesity	79,341 (24.37%)	6,273 (21.39%)	73,068 (24.66%)	<0.001
Lipid disorders	103,085 (31.66%)	6,769 (23.08%)	96,316 (32.51%)	<0.001
Comorbidities, n (%)				
Dementia	1,530 (0.47%)	49 (0.17%)	1,481 (0.50%)	<0.001
Chronic pulmonary disease	71,344 (21.91%)	4,052 (13.82%)	67,292 (22.71%)	<0.001
Rheumatic disease	6,811 (2.09%)	433 (1.48%)	6,378 (2.15%)	<0.001
Peptic ulcer disease	2,353 (0.72%)	97 (0.33%)	2,256 (0.76%)	<0.001
Mild liver disease	19,666 (6.04%)	734 (2.50%)	18,932 (6.39%)	<0.001
Diabetes without chronic complication	102,364 (31.44%)	6,054 (20.64%)	96,310 (32.51%)	<0.001
Diabetes with chronic complication	40,848 (12.55%)	1,452 (4.95%)	39,396 (13.30%)	<0.001
Hemiplegia or paraplegia	4,729 (1.45%)	140 (0.48%)	4,589 (1.55%)	<0.001
Any malignancy	10,139 (3.11%)	662 (2.26%)	9,477 (3.20%)	<0.001
Moderate or severe liver disease	3,071 (0.94%)	26 (0.09%)	3,045 (1.03%)	<0.001
Metastatic solid tumor	1,731 (0.53%)	96 (0.33%)	1,635 (0.55%)	<0.001
AIDS/HIV	3,154 (0.97%)	242 (0.83%)	2,912 (0.98%)	0.009

Abbreviations:

^a We employed the Wilcoxon nonparametric rank-sum test to examine differences in means across continuous variables, while Pearson's Chi-square test was utilized to assess variations in proportions across categorical variables based on combination-pill and multi-pill therapies.

Table 2. The Association of Combination-Pill Therapy Use with Medication Adherence and Medication Possession Ratios (per individual)^a

	All	NH White	NH Black	Hispanic
Medication Adherence (MPR \geq 80%) to Antihypertensives				
Multi-pill therapy ^b	0.395 (0.393 - 0.397)	0.444 (0.442 - 0.447)	0.309 (0.305 - 0.312)	0.386 (0.376 - 0.395)
Combination-pill therapy only ^b	0.480 (0.474 - 0.485)	0.541 (0.534 - 0.549)	0.378 (0.368 - 0.387)	0.442 (0.416 - 0.469)
Difference ^c	0.085*** (0.079 - 0.091)	0.097*** (0.089 - 0.105)	0.069*** (0.059 - 0.079)	0.057*** (0.029 - 0.085)
Observations	325,600	174,306	93,122	13,736
Medication Possession Ratios				
Multi-pill therapy	65.66 (65.53 - 65.78)	69.23 (69.06 - 69.40)	59.27 (59.04 - 59.50)	66.33 (65.72 - 66.93)
Combination-pill therapy only	68.83 (68.47 - 69.19)	73.11 (72.60 - 73.63)	61.03 (60.40 - 61.67)	69.94 (68.26 - 71.63)
Difference	3.17*** (2.79 - 3.55)	3.88*** (3.34 - 4.42)	1.76*** (1.09 - 2.44)	3.62*** (1.83 - 5.40)
Observations	325,600	174,306	93,122	13,736

^a Logistic regression was employed to analyze medication adherence, while linear regression was used for medication possession ratios. Average marginal effects, along with 95% confidence intervals, were reported. All models were adjusted for 12 Charlson comorbidities, risk factors (alcohol use, tobacco use, obesity, and lipid disorders), gender, age groups (aged 18-34, aged 35-44, aged 45-54, and aged 55-64), race/ethnicity, and fixed effects for the year and month of the index date.

^b Those who used combination-pill therapy comprise individuals who exclusively used FDC-antihypertensives during the one-year follow-up periods from the antihypertensive index date. Those who used multi-pill therapy comprise individuals who did not use FDC-antihypertensives during the one-year follow-up periods.

^c The reported differences reflect the predicted outcomes, specifically the average marginal effects, for individuals receiving combination-pill therapy compared with those receiving multi-pill therapy.

*** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$

Table 3. The Association of Combination-Pill Therapy Use with Hypertension- and Cardiovascular Disease- Related Health Care Utilization (per 1,000 individuals)^a

	Num. HTN-related ^c ED visits	Num. HTN-related Inpatient Admissions	Num. CVD-related ^d ED visits	Num. CVD-related Inpatient Admissions
All				
Multi-pill therapy ^b	697.7 (689.0 - 706.4)	227.5 (221.6 - 233.3)	768.1 (758.8 - 777.5)	261.2 (254.3 - 268.0)
Combination-pill therapy only ^b	478.1 (465.0 - 491.2)	74.78 (70.91 - 78.65)	498.0 (484.6 - 511.4)	80.33 (76.23 - 84.43)
Difference ^c	-219.6*** (-235.4 – -203.8)	-152.7*** (-159.8 – -145.6)	-270.1*** (-286.5 – -253.8)	-180.9*** (-188.8 – -172.9)
Observations	325,600	325,600	325,600	325,600
Non-Hispanic White				
Multi-pill therapy	589.4 (579.9 - 599.0)	207.4 (201.2 - 213.6)	662.5 (652.2 - 672.9)	246.3 (238.9 - 253.7)
Combination-pill therapy only	417.5 (400.3 - 434.7)	73.64 (67.97 - 79.31)	437.9 (420.3 - 455.6)	79.27 (73.28 - 85.26)
Difference	-171.9*** (-192.0 – -151.8)	-133.8*** (-142.2 – -125.4)	-224.6*** (-245.5 – -203.8)	-167.0*** (-176.6 – -157.5)
Observations	174,306	174,306	174,306	174,306
Non-Hispanic Black				
Multi-pill therapy	898.1 (882.0 - 914.1)	270.5 (261.2 - 279.8)	969.5 (952.6 - 986.5)	299.6 (289.2 - 310.0)
Combination-pill therapy only	610.8 (584.3 - 637.4)	78.38 (71.01 - 85.74)	633.0 (605.9 - 660.0)	84.55 (76.72 - 92.37)
Difference	-287.2*** (-318.0 – -256.4)	-192.1*** (-204.0 – -180.2)	-336.6*** (-368.3 – -304.9)	-215.0*** (-227.9 – -202.1)
Observations	93,122	93,122	93,122	93,122
Hispanic				
Multi-pill therapy	512.9 (488.2 - 537.6)	142.8 (131.8 - 153.8)	566.9 (540.7 - 593.1)	164.4 (152.2 - 176.6)
Combination-pill therapy only	390.3 (324.2 - 456.5)	54.48 (37.93 - 71.03)	402.7 (334.6 - 470.8)	55.87 (39.01 - 72.74)
Difference	-122.6*** (-192.4 – -52.8)	-88.3*** (-108.5 – -68.2)	-164.2*** (-236.3 – -92.2)	-108.5*** (-129.6 – -87.5)
Observations	13,736	13,736	13,736	13,736

^a A negative binomial model was used for all count variables. Average marginal effects, along with 95% confidence intervals, were reported. All models were adjusted for 12 Charlson comorbidities, risk factors (alcohol use, tobacco use, obesity, and lipid disorders), gender, age groups (aged 18-34, aged 35-44, aged 45-54, and aged 55-64), race/ethnicity and fixed effects for the year and month of the index date.

^b Those who used combination-pill therapy comprise individuals who exclusively used FDC-antihypertensive during the one-year follow-up periods from the antihypertensive index date. Those who used multi-pill therapy comprise those who did not use FDC-antihypertensive during the one-year follow-up periods.

^c The reported differences reflect the predicted outcomes, specifically the average marginal effects, for individuals receiving combination-pill therapy compared with those receiving multi-pill therapy.

^d Hypertension (HTN)-related emergency department (ED) visits and inpatient admissions are defined as those containing an HTN diagnosis (ICD-10-CM codes I10–I15). Cardiovascular disease (CVD)-related ED visits and inpatient admissions are defined as those containing a CVD diagnosis (ICD-10-CM codes I00–I78).

*** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$

Table 4. The Association of Combination-Pill Therapy Use with Medical Costs Associated with Hypertension and Cardiovascular Disease (CVD) (per individual)^a

	HTN-related total medical costs, \$	HTN-related ED costs, \$	HTN-related inpatient costs, \$	CVD-related total medical costs, \$	CVD-related ED costs, \$	CVD-related inpatient costs, \$
All						
Multi-pill therapy ^b	4,842	470	3,067	5,976	520.8	3,680
	(4,717 - 4,968)	(450.9 - 489.9)	(2,897 - 3,237)	(5,821 - 6,130)	(499.8 - 541.9)	(3,466 - 3,893)
Combination-pill therapy only ^b	1,980	245	787	2,196	252	882
	(1,858 - 2,102)	(228 - 263)	(696 - 878)	(2,064 - 2,329)	(235 - 270)	(781 - 982)
Difference ^c	-2,862***	-225***	-2,280***	-3,779***	-269***	-2,798***
	(-3,035 – -2,689)	(-251 – -199)	(-2,464 – -2,096)	(-3,978 – -3,581)	(-295 – -242)	(-3,018 – -2,578)
Observations	128,528	128,528	128,528	128,528	128,528	128,528
Non-Hispanic White						
Multi-pill therapy	3,900	379	2,604	4,976	436	3,264
	(3,765 - 4,034)	(360.2 - 397.2)	(2,422 - 2,785)	(4,809 - 5,144)	(416 - 457)	(3,035 - 3,492)
Combination-pill therapy only	1,774	208	855	1,964	216	969
	(1,603 - 1,944)	(185 - 232)	(705 - 1,005)	(1,781 - 2,147)	(192 - 240)	(804 - 1,134)
Difference	-2,126***	-171***	-1,749***	-3,012***	-220***	-2,294***
	(-2,339 – -1,912)	(-200 – -141)	(-1,972 – -1,526)	(-3,255 – -2,769)	(-252 – -189)	(-2,559 – -2,030)
Observations	60,139	60,139	60,139	60,139	60,139	60,139
Non-Hispanic Black						
Multi-pill therapy	6,235	625	3,606	7,498	679	4,202
	(5,996 - 6,474)	(593 - 657)	(3,336 - 3,876)	(7,214 - 7,783)	(645 - 713)	(3,877 - 4,527)
Combination-pill therapy only	2,339	327	693	2,584	335	783
	(2,152 - 2,526)	(293 - 360)	(575 - 811)	(2,378 - 2,790)	(302 - 369)	(649 - 916)
Difference	-3,896***	-299***	-2,913***	-4,914***	-344***	-3,419***
	(-4,198 – -3,595)	(-344 – -253)	(-3,210 – -2,616)	(-5,258 – -4,571)	(-391 – -297)	(-3,764 – -3,074)
Observations	39,326	39,326	39,326	39,326	39,326	39,326
Hispanic						
Multi-pill therapy	2,035	107	1,605	2,563	118	1,964
	(1,827 - 2,244)	(80 - 135)	(1,372 - 1,837)	(2,300 - 2,827)	(90 - 146)	(1,683 - 2,245)

Combination-pill therapy only	776.4	43	423	837	45	447
	(531.4 - 1,021)	(25 - 61)	(210 - 636)	(583 - 1,091)	(27 - 63)	(229 - 665)
Difference	-1,259***	-64***	-1,181***	-1,727***	-73***	-1,517***
	(-1,584 – -934)	(-97 – -32)	(-1,502 – -861)	(-2,095 – -1,359)	(-106 – -40)	(-1,876 – -1,159)
Observations	8,690	8,690	8,690	8,690	8,690	8,690


^a Hypertension-related and CVD-related healthcare utilization and total medical costs were defined based on the presence of respective diagnosis codes (hypertension: ICD-10-CM codes I10-I15; CVD: ICD-10-CM codes I00-I78). A generalized linear model with a gamma distribution and log link was used for all cost outcomes. Average marginal effects, along with 95% confidence intervals, were reported. All models were adjusted for 12 Charlson comorbidities, risk factors (alcohol use, tobacco use, obesity, and lipid disorders), gender, age groups (aged 18-34, aged 35-44, aged 45-54, and aged 55-64), race/ethnicity, and fixed effects for the year and month of the index date.

^b Those who used combination-pill therapy comprise individuals who exclusively used FDC-antihypertensives during the one-year follow-up periods from the antihypertensive index date. Those who used multi-pill therapy comprise those who did not use FDC-antihypertensive during the one-year follow-up periods.

^c The reported differences reflect the predicted outcomes, specifically the average marginal effects, for individuals receiving combination-pill therapy compared with those receiving multi-pill therapy.

*** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$

Figure 1. Insurance, and Patients' Out-of-Pocket Costs for Combination-Pill Therapy and Multi-Pill Therapy by Racial and Ethnic Groups, MarketScan Medicaid, 2016-2022^a



^a Those who used combination-pill therapy comprise individuals who exclusively used FDC-antihypertensives during the one-year follow-up periods from the antihypertensive index date. Those who used multi-bill therapy comprise those who did not use FDC-antihypertensives during the one-year follow-up periods.